GLS and acute lymphoblastic leukemia: Clinically used Asparaginase (ASNase) exerts its therapeutic effect on acute lymphoblastic leukemia (ALL) through its asparaginase activity, but it is limited by glutamine off-target side effects, while EmAGA also has asparaginase activity but no glutaminase activity, rendering its potential as a basis for novel anti-leukemic enzymatic therapeutics.